Work

Supplemental Figure S6 from Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer

Year: 2023

Type: supplementary-materials

Abstract: Combination of cabozantinib with PF-562271 delays tumor recurrence after treatments cessation.

DOI: 10.1158/0008-5472.22410326.v1

Authors: Yu-Chen Lee, Song-Chang Lin, Guoyu Yu, Chien-Jui Cheng, Bin Liu, Hsuan-Chen Liu, David H. Hawke, Nila U. Parikh, Andreas Varkaris, Paul Corn, Christopher Logothetis, Robert L. Satcher, Li-Yuan Yu-Lee, Gary E. Gallick, Sue-Hwa Lin

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362014434

Cites:

Cited by:

Related to: 10